Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis

Wolfgang Hueber, Dhavalkumar D. Patel, Thaddeus Dryja, Andrew M. Wright, Irina Koroleva, Gerard Bruin, Christian Antoni, Zoe Draelos, Michael H. Gold, Patrick Durez, Paul P. Tak, Juan J. Gomez-Reino, C. Stephen Foster, Rosa Y. Kim, C. Michael Samson, Naomi S. Falk, David S. Chu, David Callanan, Quan Dong Nguyen, Kristine Rose & 2 others Asifa Haider, Franco Di Padova

Research output: Contribution to journalArticle

621 Citations (Scopus)

Abstract

Interleukin-17A (IL-17A) is elaborated by the T helper 17 (TH17) subset of TH cells and exhibits potent proinflammatory properties in animal models of autoimmunity, including collagen-induced arthritis, experimental autoimmune encephalomyelitis, and experimental autoimmune uveitis. To determine whether IL-17A mediates human inflammatory diseases, we investigated the efficacy and safety of AIN457, a human antibody to IL-17A, in patients with psoriasis, rheumatoid arthritis, and chronic noninfectious uveitis. Patients with chronic plaque-type psoriasis (n = 36), rheumatoid arthritis (n = 52), or chronic noninfectious uveitis (n = 16) were enrolled in clinical trials to evaluate the effects of neutralizing IL-17A by AIN457 at doses of 3 to 10 mg/kg, given intravenously. We evaluated efficacy by measuring the psoriasis area and severity index (PASI), the American College of Rheumatology 20% response (ACR20) for rheumatoid arthritis, or the number of responders for uveitis, as defined by either vision improvement or reduction in ocular inflammation or corticosteroid dose. AIN457 treatment induced clinically relevant responses of variable magnitude in patients suffering from each of these diverse immune-mediated diseases. Variable response rates may be due to heterogeneity in small patient populations, differential pathogenic roles of IL-17A in these diseases, and the different involvement or activation of IL-17A-producing cells. The rates of adverse events, including infections, were similar in the AIN457 and placebo groups. These results support a role for IL-17A in the pathophysiology of diverse inflammatory diseases including psoriasis, rheumatoid arthritis, and noninfectious uveitis.

Original languageEnglish (US)
Article number52ra72
JournalScience translational medicine
Volume2
Issue number52
DOIs
StatePublished - Oct 6 2010

Fingerprint

Interleukin-17
Uveitis
Psoriasis
Rheumatoid Arthritis
Antibodies
Autoimmune Experimental Encephalomyelitis
Th17 Cells
Experimental Arthritis
Immune System Diseases
Autoimmunity
secukinumab
Adrenal Cortex Hormones
Animal Models
Placebos
Clinical Trials
Inflammation
Safety
Infection
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., ... Di Padova, F. (2010). Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Science translational medicine, 2(52), [52ra72]. https://doi.org/10.1126/scitranslmed.3001107

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. / Hueber, Wolfgang; Patel, Dhavalkumar D.; Dryja, Thaddeus; Wright, Andrew M.; Koroleva, Irina; Bruin, Gerard; Antoni, Christian; Draelos, Zoe; Gold, Michael H.; Durez, Patrick; Tak, Paul P.; Gomez-Reino, Juan J.; Foster, C. Stephen; Kim, Rosa Y.; Samson, C. Michael; Falk, Naomi S.; Chu, David S.; Callanan, David; Nguyen, Quan Dong; Rose, Kristine; Haider, Asifa; Di Padova, Franco.

In: Science translational medicine, Vol. 2, No. 52, 52ra72, 06.10.2010.

Research output: Contribution to journalArticle

Hueber, W, Patel, DD, Dryja, T, Wright, AM, Koroleva, I, Bruin, G, Antoni, C, Draelos, Z, Gold, MH, Durez, P, Tak, PP, Gomez-Reino, JJ, Foster, CS, Kim, RY, Samson, CM, Falk, NS, Chu, DS, Callanan, D, Nguyen, QD, Rose, K, Haider, A & Di Padova, F 2010, 'Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis', Science translational medicine, vol. 2, no. 52, 52ra72. https://doi.org/10.1126/scitranslmed.3001107
Hueber, Wolfgang ; Patel, Dhavalkumar D. ; Dryja, Thaddeus ; Wright, Andrew M. ; Koroleva, Irina ; Bruin, Gerard ; Antoni, Christian ; Draelos, Zoe ; Gold, Michael H. ; Durez, Patrick ; Tak, Paul P. ; Gomez-Reino, Juan J. ; Foster, C. Stephen ; Kim, Rosa Y. ; Samson, C. Michael ; Falk, Naomi S. ; Chu, David S. ; Callanan, David ; Nguyen, Quan Dong ; Rose, Kristine ; Haider, Asifa ; Di Padova, Franco. / Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. In: Science translational medicine. 2010 ; Vol. 2, No. 52.
@article{c87c2de54d6e49978881b5d298b74f61,
title = "Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis",
abstract = "Interleukin-17A (IL-17A) is elaborated by the T helper 17 (TH17) subset of TH cells and exhibits potent proinflammatory properties in animal models of autoimmunity, including collagen-induced arthritis, experimental autoimmune encephalomyelitis, and experimental autoimmune uveitis. To determine whether IL-17A mediates human inflammatory diseases, we investigated the efficacy and safety of AIN457, a human antibody to IL-17A, in patients with psoriasis, rheumatoid arthritis, and chronic noninfectious uveitis. Patients with chronic plaque-type psoriasis (n = 36), rheumatoid arthritis (n = 52), or chronic noninfectious uveitis (n = 16) were enrolled in clinical trials to evaluate the effects of neutralizing IL-17A by AIN457 at doses of 3 to 10 mg/kg, given intravenously. We evaluated efficacy by measuring the psoriasis area and severity index (PASI), the American College of Rheumatology 20{\%} response (ACR20) for rheumatoid arthritis, or the number of responders for uveitis, as defined by either vision improvement or reduction in ocular inflammation or corticosteroid dose. AIN457 treatment induced clinically relevant responses of variable magnitude in patients suffering from each of these diverse immune-mediated diseases. Variable response rates may be due to heterogeneity in small patient populations, differential pathogenic roles of IL-17A in these diseases, and the different involvement or activation of IL-17A-producing cells. The rates of adverse events, including infections, were similar in the AIN457 and placebo groups. These results support a role for IL-17A in the pathophysiology of diverse inflammatory diseases including psoriasis, rheumatoid arthritis, and noninfectious uveitis.",
author = "Wolfgang Hueber and Patel, {Dhavalkumar D.} and Thaddeus Dryja and Wright, {Andrew M.} and Irina Koroleva and Gerard Bruin and Christian Antoni and Zoe Draelos and Gold, {Michael H.} and Patrick Durez and Tak, {Paul P.} and Gomez-Reino, {Juan J.} and Foster, {C. Stephen} and Kim, {Rosa Y.} and Samson, {C. Michael} and Falk, {Naomi S.} and Chu, {David S.} and David Callanan and Nguyen, {Quan Dong} and Kristine Rose and Asifa Haider and {Di Padova}, Franco",
year = "2010",
month = "10",
day = "6",
doi = "10.1126/scitranslmed.3001107",
language = "English (US)",
volume = "2",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "52",

}

TY - JOUR

T1 - Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis

AU - Hueber, Wolfgang

AU - Patel, Dhavalkumar D.

AU - Dryja, Thaddeus

AU - Wright, Andrew M.

AU - Koroleva, Irina

AU - Bruin, Gerard

AU - Antoni, Christian

AU - Draelos, Zoe

AU - Gold, Michael H.

AU - Durez, Patrick

AU - Tak, Paul P.

AU - Gomez-Reino, Juan J.

AU - Foster, C. Stephen

AU - Kim, Rosa Y.

AU - Samson, C. Michael

AU - Falk, Naomi S.

AU - Chu, David S.

AU - Callanan, David

AU - Nguyen, Quan Dong

AU - Rose, Kristine

AU - Haider, Asifa

AU - Di Padova, Franco

PY - 2010/10/6

Y1 - 2010/10/6

N2 - Interleukin-17A (IL-17A) is elaborated by the T helper 17 (TH17) subset of TH cells and exhibits potent proinflammatory properties in animal models of autoimmunity, including collagen-induced arthritis, experimental autoimmune encephalomyelitis, and experimental autoimmune uveitis. To determine whether IL-17A mediates human inflammatory diseases, we investigated the efficacy and safety of AIN457, a human antibody to IL-17A, in patients with psoriasis, rheumatoid arthritis, and chronic noninfectious uveitis. Patients with chronic plaque-type psoriasis (n = 36), rheumatoid arthritis (n = 52), or chronic noninfectious uveitis (n = 16) were enrolled in clinical trials to evaluate the effects of neutralizing IL-17A by AIN457 at doses of 3 to 10 mg/kg, given intravenously. We evaluated efficacy by measuring the psoriasis area and severity index (PASI), the American College of Rheumatology 20% response (ACR20) for rheumatoid arthritis, or the number of responders for uveitis, as defined by either vision improvement or reduction in ocular inflammation or corticosteroid dose. AIN457 treatment induced clinically relevant responses of variable magnitude in patients suffering from each of these diverse immune-mediated diseases. Variable response rates may be due to heterogeneity in small patient populations, differential pathogenic roles of IL-17A in these diseases, and the different involvement or activation of IL-17A-producing cells. The rates of adverse events, including infections, were similar in the AIN457 and placebo groups. These results support a role for IL-17A in the pathophysiology of diverse inflammatory diseases including psoriasis, rheumatoid arthritis, and noninfectious uveitis.

AB - Interleukin-17A (IL-17A) is elaborated by the T helper 17 (TH17) subset of TH cells and exhibits potent proinflammatory properties in animal models of autoimmunity, including collagen-induced arthritis, experimental autoimmune encephalomyelitis, and experimental autoimmune uveitis. To determine whether IL-17A mediates human inflammatory diseases, we investigated the efficacy and safety of AIN457, a human antibody to IL-17A, in patients with psoriasis, rheumatoid arthritis, and chronic noninfectious uveitis. Patients with chronic plaque-type psoriasis (n = 36), rheumatoid arthritis (n = 52), or chronic noninfectious uveitis (n = 16) were enrolled in clinical trials to evaluate the effects of neutralizing IL-17A by AIN457 at doses of 3 to 10 mg/kg, given intravenously. We evaluated efficacy by measuring the psoriasis area and severity index (PASI), the American College of Rheumatology 20% response (ACR20) for rheumatoid arthritis, or the number of responders for uveitis, as defined by either vision improvement or reduction in ocular inflammation or corticosteroid dose. AIN457 treatment induced clinically relevant responses of variable magnitude in patients suffering from each of these diverse immune-mediated diseases. Variable response rates may be due to heterogeneity in small patient populations, differential pathogenic roles of IL-17A in these diseases, and the different involvement or activation of IL-17A-producing cells. The rates of adverse events, including infections, were similar in the AIN457 and placebo groups. These results support a role for IL-17A in the pathophysiology of diverse inflammatory diseases including psoriasis, rheumatoid arthritis, and noninfectious uveitis.

UR - http://www.scopus.com/inward/record.url?scp=77958072084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958072084&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3001107

DO - 10.1126/scitranslmed.3001107

M3 - Article

VL - 2

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 52

M1 - 52ra72

ER -